Design and Evaluation of Voriconazole Eye Drops for the Treatment of Fungal Keratitis

Table 4

Stability profile of voriconazole ophthalmic solutions containing different viscosity modifiers under accelerated conditions (40°C ± 2°C, 75% RH ± 5%).

Formulations	Drug content (%)					pH
	0 D	3 W	6 W	3 M	6 M	0 D	3 W	6 W	3 M	6 M
Control	100±0.01	97.01±0.04	97.12±0.02	97.00±0.02	94.23±0.09	7.0	6.8	6.8	6.8	6.8
XG	100±0.00	98.68±0.01	98.02±0.01	97.22±0.00	97.10±0.00	7.0	7.0	6.9	6.9	6.9
SCMC	100±0.00	98.58±0.01	97.89±0.01	97.13±0.00	96.78±0.01	7.0	7.0	6.9	6.9	6.8
Gelrite	100±0.00	98.52±0.01	97.69±0.00	97.10±0.00	96.60±0.01	7.0	6.9	6.9	6.8	6.8
NA	100±0.00	98.45±0.00	97.87±0.01	97.24±0.00	96.48±0.00	7.0	6.9	6.8	6.8	6.8
GG	100±0.01	98.28±0.00	97.92±0.01	97.56±0.00	96.36±0.01	7.0	6.9	6.8	6.8	6.8
CS	100±0.01	97.96±0.00	97.44±0.00	96.88±0.01	95.97±0.00	7.0	6.8	6.8	6.8	6.7
PVA	100±0.01	97.44±0.00	96.97±0.00	96.47±0.01	95.69±0.01	7.0	6.8	6.7	6.7	6.7

Values are mean of ± SD (𝑛=3). D: days; W: weeks; M: months.